论文部分内容阅读
目的探讨艾拉莫德对难治性类风湿关节炎患者血清肿瘤坏死因子α(TNF-α)血管内皮生长因子(VEGF)水平的影响。方法选择难治性类风湿关节炎患者96例为研究对象,随机将其分为观察组48例与对照组48例。对照组口服甲氨蝶呤治疗,观察组采用艾拉莫德治疗,比较两组TNF-α、VEGF指标变化及用药过程中不良反应。结果治疗后,两组TNF-α、VEGF水平均降低,且观察组降低更为显著,差异有统计学意义(P<0.05)。不良反应发生率对照组为20.3%(10/48),观察组为4.17%(2/48),两组比较差异有统计学意义(χ2=6.095,P<0.05)。结论难治性类风湿关节炎采用艾拉莫德治疗效果显著,可明显改善临床症状及TNF-α、VEGF指标水平,且不良反应少。
Objective To investigate the effect of iguratimod on serum tumor necrosis factor α (TNF-α) and vascular endothelial growth factor (VEGF) levels in patients with refractory rheumatoid arthritis. Methods Ninety-six patients with refractory rheumatoid arthritis were selected as study subjects, and randomly divided into observation group (48 cases) and control group (48 cases). The control group was treated with methotrexate orally. The observation group was treated with iguratimod. The changes of TNF-α and VEGF in the two groups were compared, and the side effects during the treatment were compared. Results After treatment, the levels of TNF-α and VEGF in both groups decreased, and the decrease in the observation group was more significant (P <0.05). The incidence of adverse reactions was 20.3% (10/48) in the control group and 4.17% (2/48) in the observation group. There was significant difference between the two groups (χ2 = 6.095, P <0.05). Conclusions The treatment of refractory rheumatoid arthritis with iguratimod is effective and can significantly improve the clinical symptoms and the level of TNF-α and VEGF, with less adverse reactions.